<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583125</url>
  </required_header>
  <id_info>
    <org_study_id>EOC317X1101</org_study_id>
    <nct_id>NCT03583125</nct_id>
  </id_info>
  <brief_title>Study of EOC317 in Chinese Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Dose Escalation Study of EOC317 in Chinese Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taizhou EOC Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taizhou EOC Pharma Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm phase 1, dose escalation study of EOC317 in patients with&#xD;
      advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, single-arm, phase 1, dose escalation study to evaluate the safety,&#xD;
      tolerability, pharmacokinetics, and preliminary pharmacodynamic effect of EOC317 in patients&#xD;
      with advanced solid tumors.&#xD;
&#xD;
      The study comprises a dose-escalation phase and a dose-expansion phase.&#xD;
&#xD;
        1. Dose-escalation: using 3+3 design to evaluate the safety, tolerability, and&#xD;
           pharmacokinetic profile of EOC317 at 5, 10, 20, 30, 45, 60 mg in patients with advanced&#xD;
           solid tumors, and to determine the maximum tolerated dose (MTD) and recommended dose&#xD;
           (RDE) for the dose expansion phase.&#xD;
&#xD;
        2. Dose-expansion: based on PK profile in the dose escalation phase, the dose-expansion&#xD;
           study will evaluate the safety, tolerability, and preliminary pharmacodynamic effect of&#xD;
           the RDE for EOC317 in patients with advanced solid tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 29, 2018</start_date>
  <completion_date type="Anticipated">November 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 29, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>From the initiation of protocol treatment to the occurrence of any of the following events: disease progression or disease recurrence or death from any cause, assessed up to 12 months</time_frame>
    <description>DLT and its incidence at each dose level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Overall Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Duration of Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Progression-free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day1: pre-dose; after EOC317 administration 0.5h、1h、2h、3h、4h、6h、8h、12h, Day2：24h, Day3：48h</time_frame>
    <description>Maximum Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day1: pre-dose; after EOC317 administration 0.5h、1h、2h、3h、4h、6h、8h、12h, Day2：24h, Day3：48h</time_frame>
    <description>Time at which maximum plasma concentration was observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-inf</measure>
    <time_frame>Day1: pre-dose; after EOC317 administration 0.5h、1h、2h、3h、4h、6h、8h、12h, Day2：24h, Day3：48h</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>Day1: pre-dose; after EOC317 administration 0.5h、1h、2h、3h、4h、6h、8h、12h, Day2：24h, Day3：48h</time_frame>
    <description>Elimination Half-life</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamic Markers</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Serum phosphate</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>EOC 317</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-escalation: 20 subjects will be given EOC 317 PO in increasing doses from 5 mg up to 60 mg or higher doses. One dose on Day 1, paused for 2 days, and then daily from Day 4 to Day 24.&#xD;
Dose-expansion: 120 subjects will be given EOC 317 PO QD from Day 1 to Day 21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EOC317</intervention_name>
    <description>tablet(s) PO</description>
    <arm_group_label>EOC 317</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients is able to understand and willing to sign a written informed consent.&#xD;
&#xD;
          2. Patients is willing to complete the study procedure and follow-up examinations.&#xD;
&#xD;
          3. Male or female patients, 18 years old and above.&#xD;
&#xD;
          4. Dose-escalation phase: patients with histopathologically or cytopathologically&#xD;
             confirmed advanced malignant solid tumors, including bladder cancer,&#xD;
             cholangiocarcinoma, gastric cancer, breast cancer; dose-expansion phase: patients with&#xD;
             histopathologically or cytopathologically confirmed advanced urothelial cancer,&#xD;
             cholangiocarcinoma, and hepatocellular carcinoma or other advanced solid tumor with&#xD;
             confirmed FGFR alterations.&#xD;
&#xD;
          5. Patients who have disease progression after previous standard of care therapy, or are&#xD;
             unable to tolerate standard of care therapy, or have no available standard of care&#xD;
             therapy.&#xD;
&#xD;
          6. Dose-escalation phase: measurable or unmeasurable lesion is acceptable; dose-expansion&#xD;
             phase: at least one measurable lesion.&#xD;
&#xD;
             * In accordance with the response evaluation criteria in solid tumors (RECIST v1.1),&#xD;
             measurable lesion is defined as the lesion with the longest diameter ≥10 mm and&#xD;
             thickness scanned ≤5mm in CT or MRI. For lymph node lesion, its minor axis must be&#xD;
             ≥15mm.&#xD;
&#xD;
          7. ECOG score is 0-1.&#xD;
&#xD;
          8. Expected survival is longer than 3 months.&#xD;
&#xD;
          9. No serious hematological, hepatic, or renal abnormality, in accordance with the&#xD;
             results of the following laboratory tests:&#xD;
&#xD;
               -  Hematology: neutrophil ≥1.5x10^9/L, platelet ≥75x10^9/L, hemoglobin ≥90 g/L;&#xD;
&#xD;
               -  Hepatic function: alanine aminotransferase (ALT) and aspartate aminotransferase&#xD;
                  (AST) ≤ upper limit of normal x3.0; alkaline phosphatase (ALP) ≤ upper limit of&#xD;
                  normal x2.5; total bilirubin (TBIL) ≤upper limit of normal x1.5; If there is a&#xD;
                  liver tumor, hepatic function: alanine aminotransferase (ALT) and aspartate&#xD;
                  aminotransferase (AST) ≤ upper limit of normal x5.0; If there is bone metastasis&#xD;
                  or a liver tumor, alkaline phosphatase (ALP) ≤ upper limit of normal x5.0;&#xD;
&#xD;
               -  Renal function: the creatinine clearance calculated by the Cockcroft-Gault&#xD;
                  formula must be ≥ 50 mL/min.&#xD;
&#xD;
         10. All the adverse events is recovered to ≤ CTCAE grade 1 after previous systemic&#xD;
             anti-tumor therapy (except alopecia and leukodermia; stable or ≤ CTCAE grade 2&#xD;
             neuropathy induced by previous anti-tumor therapy).&#xD;
&#xD;
         11. Effective contraceptive measures during the treatment and within 6 months after the&#xD;
             last dose for male and female patients.&#xD;
&#xD;
         12. Dose-escalation phase: collection of tumor biopsy samples will be optional;&#xD;
             dose-expansion phase: non-optional collection of tumor biopsy samples if the FGFR&#xD;
             alteration is unknown during screening period;&#xD;
&#xD;
         13. Dose-expansion phase: liver function rating Child-Pugh grade A or grade B ( score ≥7);&#xD;
&#xD;
         14. Blood pressure is effectively controlled using 0 or 1 antihypertensive drugs, (blood&#xD;
             pressure ≤150/90 mmHg), without replacing antihypertensive drugs within 1 week before&#xD;
             day 1 of cycle 1;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous use of the drug against FGFR pathway.&#xD;
&#xD;
          2. Having other malignant tumors other than the tumor treated in the study (exceptions:&#xD;
             the malignant tumors cured with no recurrence within three years before enrollment in&#xD;
             the study; completely resected basal cell and squamous cell carcinoma of skin;&#xD;
             completely resected carcinoma in situ of any type).&#xD;
&#xD;
          3. Invasion of original lesion to central nervous system (CNS) with symptoms, which is&#xD;
             unstable and requires high-dose steroid (≥10 mg Dexamethasone or equivalent dose) to&#xD;
             control it.&#xD;
&#xD;
          4. Clinically significant laboratory calcium/phosphorus abnormalities in patients even&#xD;
             after medical intervention before the first dose of study treatment, or in association&#xD;
             with parathyroid disorder or tumor lysis syndrome.&#xD;
&#xD;
          5. Ophthalmic diseases known to affect visual sensitivity, e.g., retinal/corneal/lens&#xD;
             lesions, severe glaucoma, et al.;&#xD;
&#xD;
          6. Active infection requiring systemic treatment (e.g., virus, bacteria, or fungus).&#xD;
&#xD;
          7. Receiving the following concomitant therapies prior to the start use of EOC317:&#xD;
&#xD;
               -  Use of the drugs that can prolong QT interval and/or have the risk of torsades de&#xD;
                  pointes (TdP) within 7 days after the first dose, for example, quinidine,&#xD;
                  flecainide, Ibutilide;&#xD;
&#xD;
               -  Use of amiodarone within 90 days prior to the first dose.&#xD;
&#xD;
          8. Cardiac impairment or clinically significant cardiovascular disease, including any of&#xD;
             the following:&#xD;
&#xD;
               -  Cerebrovascular accident/stroke (within 6 months before enrollment);&#xD;
&#xD;
               -  Myocardial infarction (within 6 months before enrollment);&#xD;
&#xD;
               -  Unstable angina pectoris, congestive heart failure (New York Heart Association&#xD;
                  classification ≥grade 2) or serious arrhythmia requiring drug therapy (including&#xD;
                  prolonged QT interval/QTc&gt;470 ms, pacemaker implantation); left ventricular&#xD;
                  ejection fraction (LVEF) &lt;50% in echocardiography.&#xD;
&#xD;
          9. History of active hemorrhage or gastrointestinal perforation risk in recent four&#xD;
             weeks, or unhealed wound in recent surgery.&#xD;
&#xD;
         10. Receiving the following therapies within the time period specified below prior to the&#xD;
             first dose :&#xD;
&#xD;
               -  Anticancer therapy ≤ 4 weeks;&#xD;
&#xD;
               -  Receiving other clinical trial drugs ≤ 4 weeks or ≤ 5 known half-lives (whichever&#xD;
                  comes later); major surgery ≤4 weeks prior to the start use of investigational&#xD;
                  product.&#xD;
&#xD;
         11. Long-term use of steroid, and daily use of ≥10 mg prednisone or equivalent dose (e.g.,&#xD;
             ≥0.75mg dexamethasone).&#xD;
&#xD;
         12. Past history of chronic diarrhea ≥ three years or presence of diarrhea prior to the&#xD;
             EOC317 treatment.&#xD;
&#xD;
         13. HBsAg is positive and HBV DNA copies&gt; normal range of detection; positive hepatitis C&#xD;
             antibody or HCV RNA; in patients with hepatocellular carcinoma and cholangiocarcinoma,&#xD;
             HBV tests show HBsAg-positive or HbcAb-positive, and HBV DNA ≥10^4 copies/ml or ≥2000&#xD;
             IU/ml (patients with undetectable HBV DNA after 2 weeks of standard antiviral therapy&#xD;
             can be enrolled), HCV RNA &gt;10^3 copies/ml (patients with undetectable HCV RNA after 2&#xD;
             weeks of standard antiviral therapy can be enrolled); HbsAg and anti-HCV are both&#xD;
             positive at the same time;&#xD;
&#xD;
         14. History of human immunodeficiency virus infection, or other acquired, congenital&#xD;
             immunodeficiency disease, or history of organ transplantation.&#xD;
&#xD;
         15. Known alcohol and/or drug addiction.&#xD;
&#xD;
         16. Previous history of neurological or psychiatric/behavioral disorder, e.g., epilepsy,&#xD;
             history of poor compliance.&#xD;
&#xD;
         17. Female patients with positive results of pregnancy test or who are currently lactating&#xD;
&#xD;
         18. Patients who are not suitable for participation in this trial for any other reasons in&#xD;
             investigators' judgement.&#xD;
&#xD;
         19. Dose-expansion phase: patients with hepatic encephalopathy; moderate or severe ascites&#xD;
             that could not be alleviated or requiring therapeutic abdominal puncture or drainage&#xD;
             (confirmed by B-ultrasound or CT scan within 1 week before randomization).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongming Pan, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Sir Run Run Shaw Hospital, Zhejiang, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Echo Zhao, M.D.</last_name>
    <phone>+86-021-3175 7928</phone>
    <email>Echo.Zhao@eocpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jie Li, M.S.</last_name>
    <phone>+86-021-3175 7928</phone>
    <email>jie.li@eocpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongming Pan, M.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bladder cancer</keyword>
  <keyword>cholangiocarcinoma</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>breast cancer</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

